Harmony Biosciences Holdings, Inc. Common Stock (HRMY)

Price$32.20

Value ScoreB

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-16.68%

Price vs S&P 500 (4W)3.91%

VGM Score65.10

Market Capitalization$1.86B

P/E Ratio (Annual)11.75x

All Metrics

P/CF (Annual)5.35x

Book Value / Share (Quarterly)$15.73

P/TBV (Annual)2.76x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)25.64%

Cash Flow / Share (Quarterly)$5.57

Price vs S&P 500 (YTD)-22.11%

Gross Margin (TTM)76.55%

Net Profit Margin (TTM)16.20%

EPS (TTM)$2.49

10-Day Avg Trading Volume0.77M

EPS Excl Extra (TTM)$2.49

Revenue Growth (5Y)40.31%

EPS (Annual)$2.71

ROI (Annual)15.35%

Gross Margin (Annual)77.16%

Net Profit Margin (5Y Avg)22.71%

Cash / Share (Quarterly)$11.08

P/E Basic Excl Extra (TTM)12.80x

Revenue Growth QoQ (YoY)16.59%

P/E Normalized (Annual)11.75x

ROA (Last FY)12.48%

Revenue Growth TTM (YoY)20.71%

EBITD / Share (TTM)$3.65

ROE (5Y Avg)26.30%

Operating Margin (TTM)21.08%

Cash Flow / Share (Annual)$5.69

P/B Ratio2.05x

P/B Ratio (Quarterly)1.78x

Net Income / Employee (Annual)$541,600

EV / Revenue (TTM)1.59x

Net Interest Coverage (TTM)20.21x

ROA (TTM)11.99%

EPS Growth QoQ (YoY)-29.00%

EV / EBITDA (TTM)6.72x

EPS Incl Extra (Annual)$2.71

Current Ratio (Annual)3.60x

Quick Ratio (Quarterly)3.48x

3-Month Avg Trading Volume0.89M

52-Week Price Return-8.08%

EV / Free Cash Flow (Annual)4.36x

P/E Incl Extra (TTM)12.80x

Revenue / Employee (TTM)$3,068,600

Tangible BV / Share (Quarterly)$14.29

P/S Ratio (Annual)2.15x

Asset Turnover (Annual)0.68x

52-Week High$40.87

Operating Margin (5Y Avg)25.91%

EPS Excl Extra (Annual)$2.71

CapEx CAGR (5Y)-56.63%

26-Week Price Return-8.76%

Quick Ratio (Annual)3.51x

13-Week Price Return12.94%

Total Debt / Equity (Annual)0.19x

Current Ratio (Quarterly)3.58x

Enterprise Value$1.43B

Revenue / Share Growth (5Y)39.51%

Asset Turnover (TTM)0.74x

Book Value / Share Growth (5Y)54.57%

Revenue / Employee (Annual)$2,964,000

Inventory Turnover (Annual)31.60x

Pretax Margin (Annual)24.76%

Cash / Share (Annual)$13.43

3-Month Return Std Dev33.99%

Gross Margin (5Y Avg)79.43%

Net Income / Employee (TTM)$497,000

EBITDA Interim CAGR (5Y)24.26%

ROE (Last FY)18.24%

Net Interest Coverage (Annual)29.83x

EPS Basic Excl Extra (Annual)$2.71

P/FCF (TTM)5.78x

Receivables Turnover (TTM)8.40x

EV / Free Cash Flow (TTM)4.44x

Total Debt / Equity (Quarterly)0.17x

EPS Incl Extra (TTM)$2.49

Receivables Turnover (Annual)9.66x

ROI (TTM)14.38%

P/S Ratio (TTM)2.07x

Pretax Margin (5Y Avg)23.51%

Revenue / Share (Annual)$14.83

Tangible BV / Share (Annual)$13.53

Forward P/E8.20x

Price vs S&P 500 (52W)-32.44%

P/E Ratio (TTM)12.80x

EPS Growth TTM (YoY)-5.36%

Year-to-Date Return-13.95%

5-Day Price Return1.23%

EPS Normalized (Annual)$2.71

ROA (5Y Avg)15.57%

Net Profit Margin (Annual)18.27%

Month-to-Date Return1.93%

Cash Flow / Share (TTM)$2.87

EBITD / Share (Annual)$3.97

EPS Growth (3Y)-3.01%

Operating Margin (Annual)24.00%

LT Debt / Equity (Annual)0.17x

P/CF (TTM)5.45x

ROI (5Y Avg)18.38%

P/E Excl Extra (TTM)12.80x

LT Debt / Equity (Quarterly)0.15x

EPS Basic Excl Extra (TTM)$2.49

P/TBV (Quarterly)1.96x

P/B Ratio (Annual)2.48x

Inventory Turnover (TTM)36.15x

Pretax Margin (TTM)21.97%

Book Value / Share (Annual)$15.07

Price vs S&P 500 (13W)4.69%

Beta0.97x

P/FCF (Annual)5.67x

Revenue / Share (TTM)$15.30

ROE (TTM)17.19%

52-Week Low$25.52

vGradeB

gGradeC

mGradeB

vgmGradeB

Show chart for

Earnings Surprise History

Q1 260.55est. 0.71

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

3.76

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
HRMYHarmony Biosciences Holdings, Inc. Common Stock	B	C	B	$32.20
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Harmony Biosciences is a pharmaceutical company commercializing therapies for rare neurological diseases with unmet medical needs. Its approved product WAKIX (pitolisant) treats cataplexy in narcolepsy patients through a novel H3 receptor mechanism. The company has multiple pipeline candidates targeting additional rare neurological conditions, positioning it in a specialized and underserved market segment.